Effect of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography-guided Management of Suspected Recurrent Papillary Thyroid Carcinoma: Long-term Follow-up with Tumour Marker Responses

Recombinant human thyroid-stimulating hormone-stimulated 18F-FDG PET/CT detected recurrent disease in most patients. Although subsequent treatment of 18F-FDG PET/CT-detected disease reduced tumour marker levels in most patients, markers remained detectable, suggesting that not all residual or metastatic disease had been identified, which compromised salvage therapy. This is the largest and most mature study to date reporting tumour marker responses to PET- or PET/CT-guided therapy in this setting.